European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention—part 2: flunarizine

Table 2 Flunarizine compared to placebo for migraine prophylaxis

Patient or population: migraine Intervention: prophylaxis with flunarizine Comparison: placebo
Outcomes	№ of participants (studies) Follow-up	Certainty of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects
Outcomes	№ of participants (studies) Follow-up	Certainty of the evidence (GRADE)	Relative effect (95% CI)	Risk with placebo	Risk difference with flunarizine
50% or more reduction in monthly migraine days	No data
Monthly migraine days	No data
Adverse events leading to discontinuation	188 (3 RCTs)	High	RD 0.02 (-0.03 to 0.06)	0 per 1,000	20 more per 1,000 (30 fewer to 60 more)

CI Confidence interval, RD Risk difference
GRADE Working Group grades of evidence: High certainty; we are very confident that the true effect lies close to that of the estimate of the effect
The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI)

ISSN: 1129-2377